Lewis Thorne

Lewis Thorne

Auto-generated profile, based on publicly available information

Lewis Thorne

National Hospital for Neurology and Neurosurgery, London, UK

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2019 in The Lancet
Verified
Journal Article
Open access
CMConor Mallucci
Conor Mallucci
MJMichael D Jenkinson
Michael D Jenkinson
ECElizabeth J Conroy
Elizabeth J Conroy
JHJohn C Hartley
John C Hartley
MBMichaela Brown
Michaela Brown
PBPaul M Brennan
Paul M Brennan
Insertion of a ventriculoperitoneal shunt for hydrocephalus is one of the commonest neurosurgical procedures worldwide. Infection of the implanted shunt affects up to 15% of these patients, resulting in prolonged hospital treatment, multiple surgeries, and reduced cognition and quality of life. Our aim was to determine the clinical and cost-effectiveness of antibiotic (rifampicin and clindamycin) or silver shunts compared with standard shunts at reducing infection. In this parallel, multicentre, single-blind, randomised controlled trial, we included patients with hydrocephalus of any aetiology undergoing insertion of their first ventriculoperitoneal shunt irrespective of age at 21 regional adult and paediatric neurosurgery centres in the UK and Ireland. Patients were randomly assigned (1:1:1 in random permuted blocks of three or six) to receive standard shunts (standard shunt group), antibiotic-impregnated (0·15% clindamycin and 0·054% rifampicin; antibiotic shunt group), or silver-impregnated shunts (silver shunt group) through a randomisation sequence generated by an independent statistician. All patients and investigators who recorded and analysed the data were masked for group assignment, which was only disclosed to the neurosurgical staff at the time of operation. Participants receiving a shunt without evidence of infection at the time of insertion were followed up for at least 6 months and a maximum of 2 years. The primary outcome was time to shunt failure due the infection and was analysed with Fine and Gray survival regression models for competing risk by intention to treat. This trial is registered with ISRCTN 49474281. Between June 26, 2013, and Oct 9, 2017, we assessed 3505 patients, of whom 1605 aged up to 91 years were randomly assigned to receive either a standard shunt (n=536), an antibiotic-impregnated shunt (n=538), or a silver shunt (n=531). 1594 had a shunt inserted without evidence of infection at the time of insertion (533 in the standard shunt group, 535 in the antibiotic shunt group, and 526 in the silver shunt group) and were followed up for a median of 22 months (IQR 10-24; 53 withdrew from follow-up). 32 (6%) of 533 evaluable patients in the standard shunt group had a shunt revision for infection, compared with 12 (2%) of 535 evaluable patients in the antibiotic shunt group (cause-specific hazard ratio [csHR] 0·38, 97·5% CI 0·18-0·80, p=0·0038) and 31 (6%) of 526 patients in the silver shunt group (0·99, 0·56-1·74, p=0·96). 135 (25%) patients in the standard shunt group, 127 (23%) in the antibiotic shunt group, and 134 (36%) in the silver shunt group had adverse events, which were not life-threatening and were mostly related to valve or catheter function. The BASICS trial provides evidence to support the adoption of antibiotic shunts in UK patients who are having their first ventriculoperitoneal shunt insertion. This practice will benefit patients of all ages by reducing the risk and harm of shunt infection. UK National Institute for Health Research Health Technology Assessment programme.

14 August 2017 in Advanced Functional Materials
Verified
Journal Article
Closed access
PDF file
AKAnil Kumar
Anil Kumar
ATAaron Tan
Aaron Tan
JWJoanna Wong
Joanna Wong
JSJonathan Clayton Spagnoli
Jonathan Clayton Spagnoli
JLJames Lam
James Lam
Hong LiuHong Liu
Hong Liu

19 August 2017 in Brain Pathology
Verified
Journal Article
Open access
PDF file
MTMaria Thom
Maria Thom
JLJoan Liu
Joan Liu
ABAnika Bongaarts
Anika Bongaarts
RRRoy J. Reinten
Roy J. Reinten
BPBeatrice Paradiso
Beatrice Paradiso
EAEleonora Aronica
Eleonora Aronica
Multinodular and vacuolating neuronal tumor (MVNT) is a new pattern of neuronal tumour included in the recently revised WHO 2016 classification of tumors of the CNS. There are 15 reports in the literature to date. They are typically associated with late onset epilepsy and a neoplastic vs. malformative biology has been questioned. We present a series of ten cases and compare their pathological and genetic features to better characterized epilepsy‐associated malformations including focal cortical dysplasia type II (FCDII) and low‐grade epilepsy‐associated tumors (LEAT). Clinical and neuroradiology data were reviewed and a broad immunohistochemistry panel was applied to explore neuronal and glial differentiation, interneuronal populations, mTOR pathway activation and neurodegenerative changes. Next generation sequencing was performed for targeted multi‐gene analysis to identify mutations common to epilepsy lesions including FCDII and LEAT. All of the surgical cases in this series presented with seizures, and were located in the temporal lobe. There was a lack of any progressive changes on serial pre‐operative MRI and a mean age at surgery of 45 years. The vacuolated cells of the lesion expressed mature neuronal markers (neurofilament/SMI32, MAP2, synaptophysin). Prominent labelling of the lesional cells for developmentally regulated proteins (OTX1, TBR1, SOX2, MAP1b, CD34, GFAPδ) and oligodendroglial lineage markers (OLIG2, SMI94) was observed. No mutations were detected in the mTOR pathway genes, BRAF, FGFR1 or MYB. Clinical, pathological and genetic data could indicate that MVNT aligns more with a malformative lesion than a true neoplasm with origin from a progenitor neuro‐glial cell type showing aberrant maturation.

16 June 2016 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
CCCharles Champeaux
Charles Champeaux
EWElena Wilson
Elena Wilson
CSColin Shieff
Colin Shieff
AKAkbar Ali Khan
Akbar Ali Khan
LTLewis Thorne
Lewis Thorne

31 May 2017 in Acta Neurochirurgica
Verified
Journal Article
Closed access
PDF file
SMSamir A. Matloob
Samir A. Matloob
ATAhmed K. Toma
Ahmed K. Toma
STSimon D. Thompson
Simon D. Thompson
CGChee L. Gan
Chee L. Gan
FRFergus Robertson
Fergus Robertson
LWLaurence D. Watkins
Laurence D. Watkins

1 September 2018 in Journal of Neurosurgery
Verified
Journal Article
Closed access
HAHasan Asif
Hasan Asif
CCClaudia L. Craven
Claudia L. Craven
ASAlmas H. Siddiqui
Almas H. Siddiqui
SSSyed N. Shah
Syed N. Shah
SMSamir A. Matloob
Samir A. Matloob
ATAhmed K. Toma
Ahmed K. Toma
OBJECTIVE: Idiopathic intracranial hypertension (IIH) is commonly associated with venous sinus stenosis. In recent years, transvenous dural venous sinus stent (DVSS) insertion has emerged as a potential therapy for resistant cases. However, there remains considerable uncertainty over the safety and efficacy of this procedure, in particular the incidence of intraprocedural and delayed complications and in the longevity of sinus patency, pressure gradient obliteration, and therapeutic clinical outcome. The aim of this study was to determine clinical, radiological, and manometric outcomes at 3–4 months after DVSS in this treated IIH cohort.METHODS: Clinical, radiographic, and manometric data before and 3–4 months after DVSS were reviewed in this single-center case series. All venographic and manometric procedures were performed under local anesthesia with the patient supine.RESULTS: Forty-one patients underwent DVSS venography/manometry within 120 days. Sinus pressure reduction of between 11 and 15 mm Hg was achieved 3–4 months after DVSS compared with pre-stent baseline, regardless of whether the procedure was primary or secondary (after shunt surgery). Radiographic obliteration of anatomical stenosis correlating with reduction in pressure gradients was observed. The complication rate after DVSS was 4.9% and stent survival was 87.8% at 120 days. At least 20% of patients developed restenosis following DVSS and only 63.3% demonstrated an improvement or resolution of papilledema.CONCLUSIONS: Reduced venous sinus pressures were observed at 120 days after the procedure. DVSS showed lower complication rates than shunts, but the clinical outcome data were less convincing. To definitively compare the outcomes between DVSS and shunts in IIH, a randomized prospective study is needed.